Press Releases
Search by Year
-
16 Jun 2025
Mergers & Acquisitions
bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
bioMérieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections.
-
03 Jun 2025
Business & Solutions
VETFIRE™: bioMérieux launches cutting-edge equine infectious respiratory disease testing
bioMérieux, a world leader in the field of in vitro diagnostics, today announced the launch of VETFIRE™, a ready-to-use PCR kit that makes testing for equine infectious respiratory diseases easier and faster.
-
22 Apr 2025
Business & Solutions
WATCHFIRE™ by bioMérieux: a PCR test to detect viruses and bacteria in wastewater and respond to potential infectious disease outbreaks
bioMérieux, a world leader in the field of in vitro diagnostics, today announces the launch of its WATCHFIRE™ molecular testing solution. The WATCHFIRE™ Respiratory (R) Panel, targeting 22 pathogens*, will run on the BIOFIRE® FILMARRAY® TORCH instrument, integrated with FIREWORKS™ software, to deliver real-time trending of viruses and bacteria present in wastewater samples.
-
17 Apr 2025
Financial Information
First-Quarter 2025 Business Review
Consolidated sales totaled €1,098 million in the first quarter of 2025, up 13.7% as reported from €965 million in first quarter of 2024. Organic growth (at constant exchange rates and scope of consolidation) stood at +12.7%, above expectations.
-
07 Apr 2025
Antimicrobial Resistance
bioMérieux obtains CE-marking for LUMED™ APSS™, a cutting-edge software solution to aid medical decision-making in Antimicrobial Stewardship
bioMérieux, a world leader in the field of in vitro diagnostics, announces the CE marking of LUMED™ APSS™, an advanced clinical decision support system (CDSS) designed to enhance antimicrobial stewardship programs (ASP) and improve patient outcomes.
-
18 Mar 2025
Antimicrobial Resistance
bioMérieux receives FDA 510(k) Clearance for its VITEK® COMPACT PRO, a new ID/AST system to fight against antimicrobial resistance
bioMérieux, a world leader in the field of in vitro diagnostics, announces the U.S. Food and Drug Administration (FDA) 510(k) clearance for VITEK® COMPACT PRO. This innovative system for microorganism identification (ID) and antibiotic susceptibility testing (AST) will benefit clinical laboratories to help diagnose infectious diseases and combat antimicrobial resistance, and industrial laboratories to identify contaminants for ensuring consumer safety.
-
07 Mar 2025
Financial Information
bioMérieux – 2024 Financial Results
Consolidated sales amounted to €3,980 million in 2024, up 10.3% like-for-like from €3,675 million in the prior year period. Reported growth stood at +8.3% for the period.
-
13 Feb 2025
Business & Solutions
bioMérieux launches GENE-UP® TYPER, an innovative diagnostic solution for food industries to rapidly analyze the root cause of contamination of Listeria monocytogenes
bioMérieux, a world leader in the field of in vitro diagnostics, today announces the launch of GENE-UP® TYPER, a real-time PCR solution for rapid root cause analysis in the food industry.
-
11 Feb 2025
Business & Solutions
bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid
bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid has obtained clearance from the U.S. Food and Drug Administration (FDA). This midplex molecular panel tests for 11 of the most common bacteria, viruses, and parasites associated with gastroenteritis — all from one sample, with results available in approximately one hour.
-
13 Jan 2025
Mergers & Acquisitions
bioMérieux strengthens its point of care presence with the acquisition of the immunoassay start-up SpinChip
bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has entered into an agreement to acquire SpinChip Diagnostics ASA (“SpinChip”), a privately held Norwegian diagnostics company that has developed a game-changing immunoassay diagnostics platform. The small benchtop analyzer is well adapted to near patient testing as it can deliver a result from a whole blood sample within 10 minutes with the same high-sensitivity performance as the laboratory instruments.